Structural Features Drive GLP-1 Analog Efficacy and Pharmacokinetics, Guiding Next-Gen Incretin Design

Glucagon-like peptide-1 (GLP-1) analogs are critical therapeutics for metabolic disorders like Type 2 Diabetes Mellitus and obesity, primarily by activating the GLP-1 receptor to promote insulin secretion and suppress glucagon. Despite their widespread use, the precise structural determinants governing their potent metabolic effects, receptor engagement, and pharmacokinetic profiles are complex. Understanding these molecular underpinnings is crucial for overcoming limitations of current agents, such as short half-lives or specific side effect profiles, and for rationally designing next-generation incretin therapeutics with improved efficacy and safety.

This comprehensive review synthesizes current insights into the structural determinants of GLP-1 analogs, drawing from a broad range of published studies. It systematically examines key modifications that influence receptor affinity, proteolytic stability, and systemic half-life, including N-terminal alterations, C-terminal elements, and lipidation strategies. The authors also explore how structural variations modulate signaling bias between G protein pathways and β-arrestin recruitment, and the principles behind emerging multi-receptor agonists, integrating computational approaches for peptide optimization.

The review highlights that N-terminal modifications are crucial for conferring resistance to dipeptidyl peptidase-4 (DPP-4) degradation, a key factor in prolonging peptide activity. C-terminal and backbone elements are shown to stabilize peptide helicity, which is essential for enhancing GLP-1R affinity and subsequent activation. Lipidation and albumin-binding strategies are identified as primary mechanisms for prolonging systemic exposure, significantly increasing circulating half-life and enabling long-acting agents like liraglutide and semaglutide. > Structural variation in GLP-1 analogs further modulates signaling bias, influencing the balance between G protein pathways and β-arrestin recruitment, which may impact therapeutic efficacy and side effect profiles. The principles of GLP-1 analog design are being extended to emerging multi-receptor agonists, leveraging computational approaches for advanced peptide optimization.